Novartis’ Gilenya hits targets in paediatric MS trial
admin 5th September 2017 Uncategorised 0Novartis has released top-line data showing that Gilenya significantly reduced relapses in children and adolescents with multiple sclerosis.
More: Novartis’ Gilenya hits targets in paediatric MS trial
Source: News